Table 3:
Risk of asthma exacerbations* across the other treatment groups.
| Haplotypes | BREATHE | ESTATe | followMAGICS | GALA II | PACMAN | PAGES | PASS | SAGE | SLOVENIA | SCSGES | Total Combined Results |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) for asthma exacerbations in patients treated with as-required SABA | |||||||||||
| n = 173 | N/A | N/A | n = 557 | N/A | n = 51 | N/A | n = 192 | N/A | N/A | n = 973 | |
| Arg16Gln27 vs. Gly16Glu27 | 1.28 (0.61, 2.70) |
N/A | N/A | 1.17 (0.84, 1.62) |
N/A | 0.54 (0.13, 2.31) |
N/A | 0.67 (0.36, 1.24) |
N/A | N/A | 1.00 (0.71, 1.40) I2 = 21.50% |
| Arg16Gln27 vs. Gly16Gln27 | 0.92 (0.33, 2.60) |
N/A | N/A | 1.13 (0.80, 1.60) |
N/A | 2.10 (0.26, 17.03) |
N/A | 0.80 (0.42, 1.55) |
N/A | N/A | 1.05 (0.79, 1.41) I2 = 0.00% |
| Gly16Gln27 vs. Gly16Glu27 | 1.40 (0.50, 3.97) |
N/A | N/A | 1.03 (0.73, 1.45) |
N/A | 0.26 (0.03, 2.09) |
N/A | 0.83 (0.43, 1.61) |
N/A | N/A | 0.99 (0.74, 1.32) I2 = 0.00% |
| OR (95% CI) for asthma exacerbations in patients treated with ICS monotherapy | |||||||||||
| n = 562 | n = 65 | N/A | n = 527 | n = 484 | n = 268 | n = 29 | n = 341 | n = 178 | n = 169 | n = 2,623 | |
| Arg16Gln27 vs. Gly16Glu27 | 1.21 (0.88, 1.65) |
0.74 (0.31, 1.76) |
N/A | 1.47 (1.00, 2.16) |
0.74 (0.45, 1.21) |
1.21 (0.80, 1.82) |
N/A | 0.70 (0.45, 1.09) |
0.72 (0.44, 1.18) |
1.00 (0.38, 2.62) |
0.98 (0.78, 1.23) I2 = 46.37% |
| Arg16Gln27 vs. Gly16Gln27 | 1.06 (0.72, 1.56) |
1.58 (0.58, 4.30) |
N/A | 1.22 (0.88, 1.70) |
0.96 (0.54, 1.71) |
0.99 (0.61, 1.60) |
N/A | 1.01 (0.99, 1.02) |
0.93 (0.50, 1.70) |
0.67 (0.39, 1.15) |
1.01 (0.99, 1.02) I2 = 0.00% |
| Gly16Gln27 vs. Gly16Glu27 | 1.15 (0.78, 1.70) |
0.47 (0.16, 1.37) |
N/A | 1.74 (1.15, 2.62) |
0.77 (0.43, 1.36) |
1.25 (0.78, 2.00) |
0.67 (0.34, 4.97) |
0.70 (0.43, 1.14) |
0.78 (0.43, 1.42) |
1.49 (0.55, 4.04) |
1.01 (0.77, 1.33) I2 = 46.05% |
| OR (95% CI) for asthma exacerbations in patients treated with ICS+LTRA | |||||||||||
| n = 37 | N/A | N/A | n = 203 | N/A | n = 64 | N/A | n = 34 | N/A | N/A | n = 338 | |
| Arg16Gln27 vs. Gly16Glu27 | 0.96 (0.29, 3.24) |
N/A | N/A | 1.33 (0.72, 2.45) |
N/A | 1.01 (0.44, 2.27) |
N/A | 1.11 (0.19, 6.55) |
N/A | N/A | 1.16 (0.75, 1.80) I2 = 0.00% |
| Arg16Gln27 vs. Gly16Gln27 | 1.14 (0.32, 4.07) |
N/A | N/A | 0.96 (0.60, 1.52) |
N/A | 0.43 (0.14, 1.25) |
N/A | 1.50 (0.41, 5.54) |
N/A | N/A | 0.91 (0.62, 1.34) I2 = 0.00% |
| Gly16Gln27 vs. Gly16Glu27 | 0.84 (0.25, 2.90) |
N/A | N/A | 1.39 (0.75, 2.60) |
N/A | 2.36 (0.72, 7.78) |
N/A | 0.74 (0.11, 5.04) |
N/A | N/A | 1.35 (0.83, 2.20) I2 = 0.00% |
| OR (95% CI) for asthma exacerbations in patients treated with ICS+LABA+LTRA | |||||||||||
| n = 84 | N/A | N/A | n = 129 | n = 43 | n = 168 | n = 229 | n = 33 | N/A | N/A | n = 686 | |
| Arg16Gln27 vs. Gly16Glu27 | 0.81 (0.42, 1.58) |
N/A | N/A | 0.96 (0.38, 2.44) |
0.41 (0.08, 2.14) |
0.97 (0.56, 1.68) |
1.58 (0.89, 2.83) |
0.65 (0.10, 4.31) |
N/A | N/A | 1.03 (0.75, 1.41) I2 = 2.57% |
| Arg16Gln27 vs. Gly16Gln27 | 1.53 (0.63, 3.72) |
N/A | N/A | 0.84 (0.40, 1.79) |
0.27 (0.04, 1.63) |
1.82 (0.93, 3.57) |
1.40 (0.65, 3.01) |
0.26 (0.02, 3.31) |
N/A | N/A | 1.22 (0.83, 1.79) I2 = 5.91% |
| Gly16Gln27 vs. Gly16Glu27 | 0.53 (0.21, 1.35) |
N/A | N/A | 1.13 (0.45, 2.87) |
1.52 (0.36, 6.47) |
0.53 (0.28, 1.00) |
1.13 (0.56, 2.29) |
2.48 (0.18, 34.37) |
N/A | N/A | 0.83 (0.54, 1.26) I2 = 17.70% |
*
Asthma exacerbations, asthma–related hospitalizations/emergency department visit or oral corticosteroids use. SABA, short-acting β2-agonists; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LTRA, leukotriene receptor antagonists. Odds Ratio (ORs) and corresponding 95% Confidence Intervals (CIs) were reported, adjusted for age and sex. N/A, Not applicable.